Literature DB >> 12480957

Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function.

Gert De Schoenmakere1, Dominique Chauveau, Jean-Pierre Grünfeld.   

Abstract

Two recent randomized trials pointed out the beneficial effect of enzyme replacement therapy on biochemical parameters in patients with Anderson-Fabry's disease. Clinical end-points, such as amelioration or stabilization of renal function deterioration, or improvement of left ventricular hypertrophy have not been evaluated in depth. We report the case of a patient whose moderately impaired renal function was stabilized with the start of enzyme treatment. In addition, left ventricular hypertrophy tended to regress. To our knowledge this is the first observation of clinical efficacy of the enzyme replacement therapy in Anderson-Fabry's disease in patients with moderately impaired renal function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12480957     DOI: 10.1093/ndt/18.1.33

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

1.  [Fabry disease: new clinical research--current therapeutic perspectives].

Authors:  Michael Beck
Journal:  Wien Klin Wochenschr       Date:  2003-04-30       Impact factor: 1.704

2.  Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  James F Meschia; Cheryl Bushnell; Bernadette Boden-Albala; Lynne T Braun; Dawn M Bravata; Seemant Chaturvedi; Mark A Creager; Robert H Eckel; Mitchell S V Elkind; Myriam Fornage; Larry B Goldstein; Steven M Greenberg; Susanna E Horvath; Costantino Iadecola; Edward C Jauch; Wesley S Moore; John A Wilson
Journal:  Stroke       Date:  2014-10-28       Impact factor: 7.914

Review 3.  Enzyme replacement therapy of Fabry disease.

Authors:  Joe T R Clarke; R Mark Iwanochko
Journal:  Mol Neurobiol       Date:  2005-08       Impact factor: 5.590

Review 4.  Enzyme replacement and enhancement therapies for lysosomal diseases.

Authors:  R J Desnick
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

5.  Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes.

Authors:  Teruo Kitagawa; Ken Suzuki; Nobuyuki Ishige; Toya Ohashi; Masahisa Kobayashi; Yoshikatsu Eto; Akemi Tanaka; Hideo Odaka; Misao Owada
Journal:  Pediatr Nephrol       Date:  2008-06-06       Impact factor: 3.714

Review 6.  Fabry disease in the era of enzyme replacement therapy: a renal perspective.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Pediatr Nephrol       Date:  2004-04-03       Impact factor: 3.714

7.  Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

Authors:  William R Wilcox; Maryam Banikazemi; Nathalie Guffon; Stephen Waldek; Philip Lee; Gabor E Linthorst; Robert J Desnick; Dominique P Germain
Journal:  Am J Hum Genet       Date:  2004-05-20       Impact factor: 11.025

8.  Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy.

Authors:  P Vylet'al; H Hůlková; M Zivná; L Berná; P Novák; M Elleder; S Kmoch
Journal:  J Inherit Metab Dis       Date:  2008-07-27       Impact factor: 4.982

Review 9.  The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.

Authors:  Dominique P Germain; Perry M Elliott; Bruno Falissard; Victor V Fomin; Max J Hilz; Ana Jovanovic; Ilkka Kantola; Aleš Linhart; Renzo Mignani; Mehdi Namdar; Albina Nowak; João-Paulo Oliveira; Maurizio Pieroni; Miguel Viana-Baptista; Christoph Wanner; Marco Spada
Journal:  Mol Genet Metab Rep       Date:  2019-02-06

10.  Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

Authors:  Fernando C Fervenza; Roser Torra; David G Warnock
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.